SCHEMBL3835296

SCHEMBL3835296

CCN1CCCC1CN(Cc1ccc(C(=O)Nc2ccccc2NC(=O)OC(C)(C)C)cc1)C(=O)Nc1ccc2c(c1)OCCO2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.41
MEN1 O00255 6/20 0.41
KMT2A Q03164 6/20 0.41
SMN1; SMN2 Q16637 4/20 0.41
GAA P10253 3/20 0.41
POLB P06746 3/20 0.41
ALOX12 P18054 2/20 0.41
HPGD P15428 1/20 0.41
MAPK1 P28482 1/20 0.41
RAB9A P51151 7/20 0.39
LMNA P02545 5/20 0.39
TP53 P04637 3/20 0.39
MAPT P10636 5/20 0.39
KDM4E B2RXH2 3/20 0.39
RXFP1 Q9HBX9 1/20 0.39
NPC1 O15118 6/20 0.39
MCHR2 Q969V1 1/20 0.39
MCHR1 Q99705 1/20 0.39
APOBEC3A P31941 1/20 0.38
APOBEC3G Q9HC16 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13646201 0.90 ALDH1A1 (0.40) ALDH1A1MEN1KMT2ASMN1; SMN2GAA
SCHEMBL4388358 0.88 ALDH1A1 (0.42) ALDH1A1MEN1KMT2ASMN1; SMN2GAA
SCHEMBL2473833 0.88 HDAC1 (0.50) ALDH1A1MEN1KMT2ASMN1; SMN2GAA
SCHEMBL2475880 0.87 LTA4H (0.44) ALDH1A1MEN1KMT2ASMN1; SMN2GAA
SCHEMBL3832445 0.87 ACKR3 (0.47) ALDH1A1MEN1KMT2ASMN1; SMN2GAA
SCHEMBL1497006 0.85 MAPT (0.37) ALDH1A1MEN1KMT2ASMN1; SMN2GAA
SCHEMBL3830933 0.82 NAMPT (0.49) ALDH1A1MEN1KMT2ASMN1; SMN2GAA
SCHEMBL3829603 0.82 RAB9A (0.44) ALDH1A1MEN1KMT2ASMN1; SMN2POLB
SCHEMBL3835546 0.82 PIR (0.44) ALDH1A1SMN1; SMN2POLBHPGDRAB9A
SCHEMBL3835228 0.81 RAB9A (0.43) ALDH1A1MEN1KMT2ASMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8076332-B2 N- (2-aminophenyl) benzamide derivative having urea structure SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-12-13 US disclosed
US-8076332-B2 N- (2-aminophenyl) benzamide derivative having urea structure SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-12-13 US disclosed
US-8076332-B2 N- (2-aminophenyl) benzamide derivative having urea structure SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-12-13 US disclosed
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-12-10 US disclosed
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-12-10 US disclosed
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-12-10 US disclosed
EP-2107052-A1 NOVEL N-(2-AMINOPHENYL)BENZAMIDE DERIVATIVE HAVING AN UREA STRUCTURE Santen Pharmaceutical Co., Ltd (JP) 2009-10-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE UACA, SLC14A1, ARG2 ALDH1A1 1040/4885MEN1 4006/4885KMT2A 1888/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.